Explain how the Bolar Provision under Section 107A of the Patents Act, 1970 promotes research and generic competition, while parallel safeguards consumer access to affordable patented products.

Section 107A of Patents Act, 1970 in the act incorporates Bolar provision and provision for parallel imports. Section 107A(a) states that "For the purposes of this Act, any act of making, constructing, using, selling or importing a patented invention solely for uses reasonably related to the development and submission of information required under any law for the time being in force, in India, or in a country other than India, that regulates the manufacture, construction, use, sale or import of any product; shall not be considered as an infringement of patent rights." Bolar provision allows manufacturers to begin the research and development process in time to ensure that affordable equivalent generic medicines can be brought to market immediately upon the expiry of the product patent. For private, non-commercial use, or to support research or experimentation, the Bolar provision, or more precisely the Bolar exemption, may be viewed as a particular kind of experimental use exception. The Bolar Provision is a legal strategy for preventing patent infringement. An innovation is either used or sold by a third party for specific reasons, for further study and development after it is created. Due to the implementation of the Bolar rule, generic drug manufacturers who want to grow their business in the market soon after the expiration of the innovator company's patents have the time and opportunity to perform research on the product while the patent is still in effect. In India, the Bolar provision is comparatively broader than its US equivalent. While the US provision restricts the safe harbour available to generic manufacturers to making, using, offering for sale or selling the patented invention solely for uses that are reasonably related to the development and submission of information under US federal law in the United States only, its Indian counterpart does not specify such territorial limits. Thus, a sale, even if outside India, will fall within the sweep of Section 107A if it is reasonably related to the development and submission of information required for regulatory approval under the law of the country in which the sale takes place. Parallel import provisions are provided in section 107 A (b) of the Patents Act, which says that importation of patented products by any person authorized by the Patentee will not be considered as an Infringement. Therefore, it is possible to import the patented products from the licensee of the patentee in any country without the permission of the Patentee. The purpose of Parallel import is to check the abuse of patent rights and meant to control the price of patented product. Unauthorized purchases of non-falsified goods from another nation made by the owner of intellectual property are known as parallel imports. Parallel goods, sometimes known as "grey goods," are involved in international trade and intellectual property issues. The premise behind parallel imports is that all available intellectual property rights have been used. The depletion of intellectual property rights is one of the rights' limitations. The resale, renting, loan, and other contractual uses of IP-protected products on the domestic and international markets shall be governed by the owner when a commodity has been distributed with the consent of the IP owner. Parallel imports take place when real goods are produced illegally, without the consent of the seller who owns the trademark, patent, or other intellectual property rights over such goods, with the intention of competing with the manufacturer's products which he initially sold internationally at a lower price. Parallel import is the practice of bringing legal goods produced with permission from the owner of the rights into another nation by an unlicensed manufacturer. The lawfulness of parallel imports in the country is decided by the exhaustion regimes adopted by the importing country. It relies greatly on the Doctrine of Exhaustion, which varies from country to country. Bolar Provision Promotes Research and Generic Competition in the following ways: Encourages Early Research and Development Generic manufacturers can conduct experiments and generate regulatory data before the expiry of the patent, thereby avoiding delay in market entry. Facilitates Timely Market Entry of Generics By permitting pre-expiry testing and regulatory filings, generic products can be launched immediately after patent expiration, enhancing competition. Reduces "Patent Monopoly Extension" Without the Bolar exception, patentees would enjoy a de facto extension of monopoly due to regulatory delays. Section 107A prevents such indirect extensions. Promotes Technological and Scientific Advancement The provision encourages innovation and research by allowing use of patented inventions for non-commercial experimental purposes related to regulatory compliance.